New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
Globe Newswire•01/10/2026•08:21 ET
0
Key Highlights
- ➤New ICD-10-PCS codes enable inpatient billing for SCD therapy in AKI patients requiring RRT
- ➤Code 5A1D701 covers intermittent urinary filtration and selective cytopheresis
- ➤QUELIMMUNE (SCD-PED) is FDA-approved for pediatric AKI linked to sepsis or septic conditions
- ➤NEUTRALIZE-AKI pivotal trial is evaluating SCD therapy in 339 adults with AKI
- ➤QUELIMMUNE trials showed 77% survival versus standard care and approximately 50% lower mortality
Expert Statements
Tim Varacek, Senior Vice President of Commercial and Business Operations of SeaStar Medical
“Availability of these unique ICD-10-PCS codes represents a significant milestone for our company and the clinical community.”
Tim Varacek, Senior Vice President of Commercial and Business Operations of SeaStar Medical
“This will simplify the hospital coding process, and importantly, support our mission to broaden access to QUELIMMUNE therapy for children with AKI who are facing permanent organ damage and loss of life.”
Tim Varacek, Senior Vice President of Commercial and Business Operations of SeaStar Medical
“The procedure codes are broadly indicated for the treatment of all patients with AKI who require RRT and we expect these designations will enable a streamlined path for the adoption of our SCD therapy for adult patients with AKI, if approved.”
New codes streamline hospital billing, enable tracking of clinical outcomes, and expand access to QUELIMMUNE (®) (SCD-PED) therapy
Universal codes establish a framework to enable billing for future potential SCD indications that require renal replacement therapy
Get started
Create a free account to read the full story.